Overview

  • Generation of cell lines with CRISPR-mediated gene knockout, mutation knocking
  • Genome-wide screening for target identification and validation
  • Human and mouse CRISPR knockout libraries
  • Human CRISPR activation libraries
  • Fast generation of GEMMs for genetic disease
  • Gene therapy

In vivo CRISPR animal models and services

High Efficiency Genome Editing Service for Drug Discovery

From genome editing to disease models and PK-PD-efficacy studies

In Vivo CRISPR Platform for Rare Disease

  • Well-established in vivo gene editing platform in rodent
  • Generation of genetically engineered animal models (GEAM) for drug discovery in rare disease
  • 30+ knockin and knockout mouse lines generated last year

Efficacy Evaluation and MoA Research Platform

  • Well-established in vitro, ex vivo and in vivo bioassay platforms
  • Multiple routes for drug administration, animal and tissue manipulation and histopathology

Knockout Services

  • CRISPR/CAS9 based knockout in mouse, rat
  • ES cell based knockout in mouse

Knockin Services

  • CRISPR/CAS9 based knockin in mouse, rat
  • ES cell based knocking in mouse

Humanization Services

  • In situ replace mouse gene with matched human exons or introns
  • Express human cDNA under the control of mouse promoter

Transgenic Services

  • Random integration into genome
  • Targeted transgene into Rosa26 or other site

Genotyping and Phenotyping Services

  • Analyze the genotype of mice and cells by PCR, Southern Blot or NGS
  • Characterization of disease mouse models

Other Services

  • In vitro fertilization
  • Embryo and sperm cryopreservation

Compliance and Accreditations

  • AAALAC accredited facility
  • OECD – received a statement of GLP compliance from the Belgium regulatory authorities
  • Chinese SFDA – received certificate of GLP compliance
  • WuXi has conducted IND and NDA enabling studies for submission to the US FDA